We are on site at the Moscone Center in San Francisco, California at the 2020 Genitourinary Cancers Symposium!
We’ll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Dr Mary Ellen Taplin on some of the biggest updates in prostate cancer, and Dr Guru Sonpavde on some of the top bladder cancer abstracts.
Welcome to OncLive News Network! I’m Gina Columbus.
In prostate cancer, a randomized phase II study evaluating sipuleucel-T with radium-223 dichloride showed that the combination led to improved clinical outcomes compared with sipuleucel-T alone in patients with asymptomatic bone-metastatic castrate-resistant disease.
Due to the fact that neither sipuleucel-T nor radium-223 elicit prostate-specific antigen responses, the findings suggest that the combination may have a synergistic effect.
In a cohort of the phase Ib COSMIC-021 trial, the combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.
Results showed that the combination elicited an overall response rate of 32%, including 2 complete responses and 12 partial responses, in the overall cohort of patients with mCRPC. In a subgroup of patients with high-risk clinical features, which included those with visceral metastases and/or extra-pelvic lymph node metastases, the ORR was 33%.
In metastatic castration-sensitive prostate cancer, a post-hoc analysis of the phase III TITAN trial showed that the addition of the antiandrogen apalutamide to androgen deprivation therapy leads to a reduction in the risk of second progression, regardless of whether patients receive hormonal therapy or a taxane as their first survival-prolonging subsequent treatment.
The TITAN trial previously demonstrated an improvement with radiographic progression-free survival and overall survival when adding apalutamide to ADT in this patient population. Based on these initial data, the FDA approved apalutamide in September 2019 for the treatment of patients with metastatic castration-sensitive prostate cancer.
In the multicohort, phase II KEYNOTE-199 trial, combining pembrolizumab with enzalutamide showed modest antitumor activity in patients with RECIST-measurable and bone-predominant metastatic castration-resistant prostate cancer.
In the 2 cohorts, the androgen receptor inhibitor and PD-1 inhibitor regimen also had a manageable safety profile. The combination will now be evaluated in a phase III trial.
Finally, an analysis of the CARD study showed that cabazitaxel was linked with a greater pain response and a delay in pain progression compared with an androgen receptor inhibitor in patients with metastatic castration-resistant prostate cancer.
While both agents were associated with similar trends in health-related quality of life, the Functional Assessment of Cancer Therapy-Prostate deterioration was longer with cabizataxel compared with an AR inhibitor.
That’s all for today. Stay tuned for tomorrow’s OncLive News Network: On Location, where we will sit down with Dr Laurence Albiges on the latest in kidney cancer, and Dr Matthew Galsky on more practice-changing bladder cancer studies.
Thank you for watching OncLive News Network! I’m Gina Columbus.